By Charles T. Saldarini, CEO, Sentrx With the biopharmaceutical industry’s increasing emphasis on safety, global adverse event (AE) management is receiving renewed attention. The challenge…
By Dax Kiger, director of strategic development, UniversalProcon & Trifecta Multimedical A clinical study manager recently wrote to me and asked, “What is the ideal…
By Mark P. Wade, global practice leader, Lionbridge Life Sciences Pharmaceutical companies have long recognized the complexity of juggling multiple variables at the outset of…
By Bill Allbee, PMP, founder & principal consultant, ABS Pharma Projects, LLC Life sciences product development has been described as navigating a path through a…
By Efraim Roe, executive director of medical devices, and Patrick Young, executive director of clinical monitoring services, Premier Research Group Medical device companies are outsourcing…
By Joshua Schultz, coporate VP of clinical research services, PAREXEL International The pressure to accelerate time-to-market for innovative biopharmaceutical products has never been more intense.…